Research programme: drug discovery - Allergan/ExonHit

Drug Profile

Research programme: drug discovery - Allergan/ExonHit

Alternative Names: AGN 002; EHT 002; EHT/AGN 0002; EHT/AGN 0003; EHT/AGN 002

Latest Information Update: 05 Aug 2015

Price : $50

At a glance

  • Originator Allergan; ExonHit Therapeutics
  • Developer Allergan; Diaxonhit
  • Class Antibodies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Eye disorders; Neurodegenerative disorders; Pain

Most Recent Events

  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
  • 16 Mar 2011 Preclinical development is ongoing in France
  • 04 Mar 2010 Back-up compounds to AGN 209323 including EHT/AGN 002 licensed to Bristol-Myers Squibb worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top